{"schema_version":"1.0","type":"article","title":"Fish oil Vascepa wins on survival, not a label","url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en.md","lang":"en","date":"2026-10-29","publish_at":"2026-10-29T08:00:00+08:00","updated_at":"2026-10-29","category":"醫學大會","topic":"醫學大會","tags":["fish oil","colorectal cancer","Vascepa","Amarin","ESMO 2026"],"summary":"VITAL said fish oil does not prevent cancer. At ESMO 2026, Amarin's Vascepa lifted 5-year survival after colorectal liver surgery to 62.0% from 45.1%, yet recurrence was unchanged and the placebo was mineral oil again.","key_points":["Amarin will not submit a colorectal cancer marketing application for Vascepa (icosapent ethyl) to the FDA or EMA before December 31, 2027, because the EMT2 phase 3 presented at ESMO on October 25, 2026 missed its primary endpoint of progression-free survival (HR 0.89, p=0.33).","EMT2 randomized 418 patients undergoing liver resection for colorectal cancer metastases; estimated 5-year overall survival was 62.0% on Vascepa 4 g/day versus 45.1% on a mineral oil placebo (HR 0.68, p=0.030), with no excess bleeding or atrial fibrillation.","EMT2's 4,000 mg/day of EPA is 22 times the roughly 180 mg of EPA in a typical 1,000 mg fish oil capsule; the VITAL trial of 25,871 people taking 460 mg EPA a day found no reduction in cancer (HR 1.03)."],"facts":[{"claim":"EMT2 phase 3 patients randomized","value":418,"unit":"people","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 liver surgery centres in England and Wales","value":13,"unit":"centres","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 Vascepa daily dose","value":4,"unit":"g","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 median PFS, Vascepa arm","value":13.5,"unit":"months","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 median PFS, placebo arm","value":12.9,"unit":"months","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 PFS hazard ratio (primary endpoint, p=0.33)","value":0.89,"unit":"HR","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 estimated 5-year overall survival, Vascepa arm","value":62,"unit":"%","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 estimated 5-year overall survival, placebo arm","value":45.1,"unit":"%","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 overall survival hazard ratio (p=0.030)","value":0.68,"unit":"HR","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"Amarin Q2 2026 total net revenue","value":42.2,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin Q2 2026 total revenue decline year over year","value":42,"unit":"%","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin Q2 2026 U.S. product revenue","value":32.2,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Recordati upfront payment included in Amarin Q2 2025 revenue","value":25,"unit":"USD million","as_of":"2025-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin cash at June 30, 2026","value":314.6,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"STRENGTH (Epanova) patients enrolled","value":13078,"unit":"people","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"STRENGTH cardiovascular event hazard ratio","value":0.99,"unit":"HR","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT placebo arm hsCRP increase","value":32,"unit":"%","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT placebo arm LDL cholesterol increase","value":10.2,"unit":"%","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT relative reduction in major cardiovascular events","value":25,"unit":"%","as_of":"2020-09-16","source":"https://www.ajmc.com/view/the-reduce-it-study-and-cv-risk"},{"claim":"VITAL participants","value":25871,"unit":"people","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"VITAL daily EPA dose","value":460,"unit":"mg","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"VITAL invasive cancer hazard ratio, omega-3 arm","value":1.03,"unit":"HR","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"EPA per typical 1,000 mg fish oil softgel","value":180,"unit":"mg","as_of":"2026-10-26","source":"https://german-drugstore.com/product/doppelherz-omega-3-sea-fish-oil-80-capsules/"},{"claim":"Maximum value of Eddingpharm deal for Vascepa rights in China, Hong Kong, Macau and Taiwan","value":169,"unit":"USD million","as_of":"2015-02-27","source":"https://www.biospace.com/b-eddingpharm-b-gains-china-rights-to-amarin-s-omega-3-product-in-169-million-deal"},{"claim":"Taiwan new cancer diagnoses in 2023 (colorectal cancer ranked second)","value":"over 138,000","unit":"people","as_of":"2025-12-30","source":"https://news.pts.org.tw/article/788225"}],"sections":["01｜Seventeen more points of survival, and the cancer came back just as fast","02｜The same mineral oil was on trial seven years ago","03｜Amarin needs this story more than patients do","04｜The fish oil on the pharmacy shelf is not this drug","05｜62% versus 45% is an invitation","References"],"references":[{"title":"Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2","source":"Amarin (GlobeNewswire","date":"2026-10-25","url":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"title":"Amarin Provides Update on EMT2: A colorectal cancer trial missed its goal, but estimated 5-year survival was 62%","source":"StockTitan","date":"2026-10-25","url":"https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html"},{"title":"EMT2 at ESMO 2026: Eicosapentaenoic Acid After Colorectal Cancer Liver Metastasis Resection","source":"OncoDaily","date":"2026-10-25","url":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"title":"EPA for Metastasis Trial 2 (NCT03428477","source":"ClinicalTrials.gov","date":"2026-10-26","url":"https://clinicaltrials.gov/study/NCT03428477"},{"title":"Amarin Reports Second Quarter 2026 Financial Results (Exhibit 99.1, Form 8-K","source":"SEC EDGAR","date":"2026-07-29","url":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"title":"Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT","source":"TCTMD","date":"2020-11-15","url":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"title":"The REDUCE-IT Study and CV Risk","source":"AJMC","date":"2020-09-16","url":"https://www.ajmc.com/view/the-reduce-it-study-and-cv-risk"},{"title":"One gram a day of omega-3 supplements does not reduce the risk of cancer or cardiovascular disease (VITAL","source":"NIHR Evidence","date":"2019-03-26","url":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"title":"Red blood cell EPA levels and survival in the EMT trial (Prostaglandins, Leukotrienes and Essential Fatty Acids 115:60–66","source":"White Rose Research Online","date":"2016-12-01","url":"https://eprints.whiterose.ac.uk/105833"},{"title":"2023 Taiwan cancer registry: over 138,000 new cases, colorectal cancer second","source":"PTS News","date":"2025-12-30","url":"https://news.pts.org.tw/article/788225"},{"title":"Eddingpharm gains China rights to Amarin's omega-3 product in $169 million deal","source":"BioSpace","date":"2015-02-27","url":"https://www.biospace.com/b-eddingpharm-b-gains-china-rights-to-amarin-s-omega-3-product-in-169-million-deal"},{"title":"Doppelherz Omega-3 Sea Fish Oil 1000 (180 mg EPA + 120 mg DHA per capsule","source":"German Drugstore","date":"2026-10-26","url":"https://german-drugstore.com/product/doppelherz-omega-3-sea-fish-oil-80-capsules/"}],"images":[{"alt":"Fig. 1｜What Vascepa did in patients after liver surgery","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/figure-01.png"},{"alt":"Fig. 2｜EMT2's two endpoints point in opposite directions","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/figure-02.png"},{"alt":"Fig. 3｜Four big fish oil trials: the control arm decided the outcome","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/figure-03.png"},{"alt":"Fig. 4｜A 22-fold gap in EPA dose","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-29）。Fish oil Vascepa wins on survival, not a label。https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}